NAGE FY 2024 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$100M+19.2% YoY

Gross Profit

$62M61.8% margin

Operating Income

$8M7.8% margin

Net Income

$9M8.6% margin

EPS (Diluted)

$0.11

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$68M

Total Liabilities

$22M

Stockholders' Equity

$46M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100M	$84M	+19.2%
Gross Profit	$62M	$51M	+21.3%
Operating Income	$8M	-$6M	+238.0%
Net Income	$9M	-$5M	+273.1%